Researchers, Students and Staff Members
Our researchers have been recognized by many national and international organizations. To name just a few examples, François Rousseau (2015) and Michel Alary (2016) have both been elected to the Canadian Academy of Health Sciences. The latter also won the 2015 Researcher Emeritus Award from the FRQS Quebec Population Health Research Network and was awarded a $4.6M grant in the first CIHR Foundation Grant competition. France Légaré and Michel Labrecque were named among the Top 20 Pioneers of Family Medicine Research in Canada in 2015, and the later was awarded the 2014 Family Medicine Researcher of the Year Award.
Michel G. Bergeron is the 2017 Canadian Medical Hall of Fame Laureate and won the 2016 Ernest C. Manning Foundation Principal Award for developing and commercializing the rapid <1hr molecular diagnostics, that identifies micro-organisms using their DNA. Gary Kobinger was named Radio-Canada’s Scientist of the Year in 2016 for his contribution to the fight against Ebola and the development of a drug and a vaccine against this virus. Emmanuel Bujold was the recipient of the 2015 Research Excellence Award from the Association of Academic Professionals in Obstetrics and Gynaecology of Canada, while Jean-Claude Forest was awarded the Canadian Medical Association Service Medal in 2017.
In 2015, Guy Poirier was a recipient of the Tony Pawson Proteomics Award from the Canadian National Proteomics Network and received a doctorate honoris causa from the Université de Rennes 1. That same year, Josée Savard was elected Fellow of the Canadian Psychological Association and Lucie Germain was named “Personality of the week” by La Presse. Marc Ouellette, Scientific Director of the CIHR Institute of Infection and Immunity, was awarded the 2015 Public Service Award of Excellence by the Governor General of Canada, along with the other members of the Ebola Response Team for their collaborative work on the management of the Ebola crisis. Jacques Simard is the recipient of the 2017 ACFAS Léo Pariseau Award.
Grants, Awards and Scholarships, Contracts, Partnerships and Sponsorships
Despite challenging economic times and a significant decrease in the number of research contracts from pharmaceutical companies in academia, our Research Centre has managed to do well, both in terms of grants and the recognition of our researchers and students. Canada's Top 40 Research Hospitals ranks the CHU de Québec-Université Laval Research Centre ninth in Canada, with almost $97 million in research revenue for 2016, an increase of $15 million since 2013. Research revenues include all funds supporting research in the form of grants, contributions or contracts.
A collaboration between the CERVO Brain Research Centre, the CHU de Québec-Université Laval Research Centre (Serge Rivest) and the COPL led to the obtaining of a major grant worth $26 million from the CFI and the Government of Quebec for neurophotonics equipment.
Partnerships, sponsorships and contracts
Awards and scholarships
Organization budget (FRQS)
Research support fund (Government of Canada)
Scientific Publications and Outreach
Researchers at our Centre have also performed well in terms of both the number and quality of scientific publications in major journals that have a high impact factor. Here are some examples: in order to characterize the genetic basis of the human microglial cell, David Gosselin carried out a study in which he characterized, with unprecedented accuracy, the molecular mechanisms behind the function of this cell in the human brain. This study, published in the prestigious journal Science in 2017, identified the gene regulation mechanisms expressed by human microglia and revealed many of its mysteries that had remained unknown until today. Robert Jr Laforce and the other members of the Genetic Frontotemporal Dementia Initiative international team reported that cognitive changes can be identified 5 to 10 years prior to the onset of symptoms in asymptomatic adults at risk of genetic frontotemporal dementia (Lancet Neurol, 2015). Steve Lacroix has demonstrated the importance of soluble interleukin-1 cell signalling in the development of inflammation and cerebral autoimmunity leading to demyelination in multiple sclerosis (J Exp Med, 2016). Serge Rivest and Marie-Ève Tremblay have demonstrated the crucial role played by the receptor CX3CR1 in the remyelination process in a mouse model of progressive multiple sclerosis (J Exp Med, 2015), a mechanism affected with age (Curr Biol, 2016). Marie-Ève Tremblay and her colleagues have demonstrated that kidney-resident macrophages play a crucial physiological function in the monitoring of circulating particles, which allows them to initiate an inflammation response in pathological conditions (Cell, 2016).
A group of 7 researchers from the Oncology axis is part of a collective of 70 researchers who published, in 2017, in the journal Nature, an article entitled “Genomic hallmarks of localized, non-indolent prostate cancer”. This article presents the results of exhaustive genomic analyses performed on the whole-genome sequences of 200 tumours and the whole-exome sequences of 477 intermediate-risk prostate tumours. Thanks to the use of advanced genome editing technologies and proteomics, Jacques Côté's team, in collaboration with Amélie Fradet-Turcotte and Yannick Doyon, published an article in the journal Molecular Cell in 2016 about a brand new mechanism demonstrating that the TIP60 complex contains a subunit called MBTD1.
An international study shows that the transfusion of fresh blood does not result in benefits for critically ill patients. Indeed, mortality and organ dysfunction rates in intensive care unit patients are independent of the storage time of transfused blood (New England Journal of Medicine). Finally, an international collaboration has identified 72 new genetic variants that contribute to the risk of developing breast cancer. Jacques Simard is one of the lead authors who oversaw the works published in 2017 in Nature and Nature Genetics. At the end of his four-year research project, Dr. Simard obtained data that will allow a better genetic knowledge of breast cancer, and that will facilitate the implementation of an effective early screening for women at higher risk.